- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02282254
Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia
An Open-label, Randomized, Cross-over Study to Assess the Efficacy of Single-hormone and Dual-hormone Closed-loop Strategy in Regulating Overnight Glucose Levels in Type 1 diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop strategy would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
The main objective of this project is to compare the efficacy of single-hormone and dual-hormone closed-loop strategy to regulate overnight glucose levels in a in-patient study in type 1 diabetes adults with hypoglycemia unawareness and documented nocturnal hypoglycemia.
The investigators hypothesized that dual-hormone closed-loop strategy is more effective in regulating overnight glucose levels compared to single-hormone closed-loop strategy.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop strategy would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
The investigators aim to conduct the 1st randomized cross-over trial comparing single- hormone and dual-hormone closed-loop strategy to regulate overnight glucose levels. The investigators aim to compare the two interventions for 10 hours in two subgroups of adults with type 1 diabètes. Patients from both subgroups will present documented nocturnal hypoglycemia. One subgroup will consist of patients with hypoglycemia unawareness while the other subgroup will consist of patients with hypoglycemia unawareness. This study will allow to determine if there is a greater benefit of a closed-loop strategy in a higher-risk hypoglycemia unaware group.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Quebec
-
Montreal, Quebec, Kanada, H2W 1R7
- Institut de Recherches Cliniques de Montreal
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Males and females ≥ 18 years of old.
- Clinical diagnosis of type 1 diabetes for at least one year.
- The subject will have been on insulin pump therapy for at least 3 months.
- HbA1c ≤ 12%.
- Hypoglycemia awareness or unawareness assessed by a questionnaire.
- Documented NH during the run-in period.
Exclusion Criteria:
- Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.
- Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
- Pregnancy.
- Severe hypoglycemic episode within two weeks of screening.
- Current use of glucocorticoid medication (except low stable dose).
- Known or suspected allergy to the trial products or snack contents.
- Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
- Anticipating a significant change in exercise regimen between admissions (i.e. starting or stopping an organized sport).
- Failure to comply with team's recommendations (e.g. not willing to eat snacks, not willing to change pump parameters, etc).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Single-hormone closed-loop strategy
|
Subjects will be admitted at the research facility at 19:00.
A cannula will be inserted into an arm or a hand vein for blood sampling purposes.
On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed.
At 20:30, a snack containing 20g of carbohydrate will be given.
Closed-loop strategy will start at 20:00 until 7:00 next morning.
A glucose sensor reading will be entered manually in a tablet every 10 minutes.
The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits).
Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
|
Aktiver Komparator: Dual-hormone closed-loop strategy
|
Subjects will be admitted at the research facility at 19:00.
A cannula will be inserted into an arm or a hand vein for blood sampling purposes.
On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed.
At 20:30, a snack containing 20g of carbohydrate will be given.
Closed-loop strategy will start at 20:00 until 7:00 next morning.
A glucose sensor reading will be entered manually in a tablet every 10 minutes.
The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits).
Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Percentage of time of plasma glucose levels spent below 4 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Gesamtinsulinabgabe
Zeitfenster: Bis zu 8 Stunden
|
Bis zu 8 Stunden
|
Percentage of time of plasma glucose levels spent between 4 and 8 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Percentage of time of plasma glucose levels spent below 3.5 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Percentage of time of plasma glucose levels spent below 3.3. mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Percentage of time of plasma glucose levels spent above 8 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Percentage of time of plasma glucose levels spent above 10 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Area under the curve of plasma glucose levels spent below 4 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Area under the curve of plasma glucose levels spent below 3.5 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Area under the curve of plasma glucose levels spent below 3.3 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Area under the curve of plasma glucose levels spent above 8 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Area under the curve of plasma glucose levels spent above 10 mmol/L
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Mean plasma glucose levels
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Standard deviation of plasma glucose levels
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Total glucagon delivery
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Number of subjects experiencing at least one hypoglycemic event requiring oral treatment
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Total number of hypoglycemic events requiring treatment
Zeitfenster: Up to 8 hours
|
Up to 8 hours
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Störungen des Glukosestoffwechsels
- Stoffwechselerkrankungen
- Erkrankungen des Nervensystems
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen
- Neurologische Manifestationen
- Neurobehaviorale Manifestationen
- Erkrankungen des endokrinen Systems
- Bewusstseinsstörungen
- Diabetes Mellitus
- Diabetes mellitus, Typ 1
- Hypoglykämie
- Bewusstlosigkeit
Andere Studien-ID-Nummern
- CLASS-09
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Typ 1
-
Eledon PharmaceuticalsZurückgezogenSpröder Diabetes mellitus Typ 1Vereinigte Staaten
-
Shanghai Jiao Tong University School of MedicineRekrutierung
-
Hadassah Medical OrganizationUnbekanntUnkontrollierte Typ-1-Diabetiker
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AbgeschlossenDiabetes mellitus Typ 1 | T1DM | T1D | Neu aufgetretener Diabetes mellitus Typ 1Vereinigte Staaten, Australien
-
Capillary Biomedical, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, insulinabhängig, 1Australien
-
Shanghai Changzheng HospitalRekrutierungSpröder Diabetes mellitus Typ 1China
-
Spiden AGDCB Research AGRekrutierungDiabetes mellitus Typ 1 | Diabetes mellitus Typ 1 mit Hypoglykämie | Diabetes mellitus Typ 1 mit HyperglykämieSchweiz
-
Capillary Biomedical, Inc.BeendetDiabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Diabetes mellitus, insulinabhängig, 1 | IDDMÖsterreich
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnbekanntDiabetes mellitus Typ 1 mit Hyperglykämie | Diabetes mellitus Typ 1 mit HypoglykämiePolen
-
Poznan University of Medical SciencesUnbekanntDiabetes mellitus Typ 1 | Remission von Typ-1-Diabetes | Chronische Komplikationen von DiabetesPolen
Klinische Studien zur Overnight intervention
-
PepsiCo Global R&DAbgeschlossenBlutzucker; Subjektiver Hunger, InsulinKanada
-
University of FloridaAbgeschlossenEmpfindlichkeitVereinigte Staaten
-
Thomas Jefferson UniversityRekrutierungProstatakarzinomVereinigte Staaten
-
Rabin Medical CenterAcademic College of Tel Aviv-Jaffa; Israel Cancer AssociationUnbekanntEierstockkrebs | Krebs des Gebärmutterhalses | Krebs des EndometriumsIsrael
-
Biolux Research Holdings, Inc.BeendetKieferorthopädische ZahnbewegungKanada
-
German Institute of Human NutritionBeneo GmbHAbgeschlossenDiabetes mellitus, Typ 2 | Metabolisches SyndromDeutschland
-
University of WashingtonNational Cancer Institute (NCI)AbgeschlossenMelanom | Lymphom | Gebärmutterhalskrebs | Leukämie | Brustkrebs | Darmkrebs | Darmkrebs | Bösartige NeubildungVereinigte Staaten
-
University of Kansas Medical CenterAbgeschlossen
-
University MariborNoch keine RekrutierungHerzkrankheiten | Herz-Kreislauf-Erkrankungen | Koronare Herzkrankheit | Koronare Herzerkrankung | Lebensstil | Kontinuierliche Glukoseüberwachung | Verhaltensänderung | CGM | Visualisierung | Visuelle Analyse
-
Ohio State University Comprehensive Cancer CenterAbgeschlossenHumanes Papillomavirus-assoziiertes KarzinomVereinigte Staaten